首頁 > 市場調查報告書 > 製藥

藥物開發臨床實驗臨床開發

市場調查報告書

商品編碼

2039029

周邊神經病變治療市場：依適應症、治療方法、最終使用者和地區分類。

Peripheral Neuropathy Treatment Market, By Indication, By Treatment, By End User, By Geography

出版日期: 2026年04月15日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，周邊神經病變治療市場規模將達到 20.719 億美元，到 2033 年將達到 25.647 億美元。預計從 2026 年到 2033 年，該市場將以 3.1% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	2,071,900,000 美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	3.10%	2033年市場規模預測：	25.647億美元

全球周邊神經病變治療市場在神經系統治療市場中佔據重要佔有率，涵蓋周邊神經系統疾病引起的常見病症的治療。這些疾病的特徵是疼痛、麻木、刺痛和肌肉無力等症狀，嚴重影響患者的生活品質。這些疾病的病因多種多樣，包括糖尿病、化療引起的神經毒性、自體免疫反應、感染疾病和遺傳因素。

由於全球糖尿病盛行率不斷上升、老年人口不斷成長以及人們對神經病變疾病的認知不斷提高，市場正經歷顯著成長。這些因素導致需要接受治療的患者人數增加。醫療機構和周邊神經病變藥物生產商正致力於研發新的治療方法不僅可以控制症狀，還能在一定程度上延緩疾病進展。

市場動態

全球周邊神經病變治療市場的主要驅動力是糖尿病盛行率的不斷上升。糖尿病是神經病變最常見的原因，近50%的糖尿病患者會出現神經病變，因此需要持續治療的患者群大規模。此外，隨著癌症病例的增加，存活率的提高使得人們更加重視治療副作用的管理，導致化療引起的周邊神經病變（CIPN）病例激增。老年人口的成長也是推動市場成長的重要因素。

然而，周邊神經病變的異質性帶來了許多挑戰，使得此疾病的診斷和治療相當困難。此外，創新藥物（尤其是鎮痛藥）的監管流程繁瑣，以及高品質治療方法的高成本，阻礙了其廣泛應用，尤其是在開發中國家。另外，缺乏可靠的生物標記也減緩了新藥的研發和測試速度。儘管如此，緩解疾病藥物和數位健康技術（包括遠端患者監護和遠端醫療）的開發仍具有巨大潛力。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數對全球周邊神經病變治療市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球周邊神經病變治療市場報告的目標對象包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等產業相關人員。
透過分析全球周邊神經病變治療市場時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第8章競爭情勢

Pfizer Inc.
Eli Lilly and Company
Novartis AG
Johnson &Johnson
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd.
Abbott Laboratories
AstraZeneca PLC
Sanofi
Merck &Co., Inc.

第9章分析師建議

機會
分析師意見
連貫的機會地圖

第10章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI4363

Peripheral Neuropathy Treatment Market is estimated to be valued at USD 2,071.9 Mn in 2026 and is expected to reach USD 2,564.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2,071.9 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	3.10%	2033 Value Projection:	USD 2,564.7 Mn

Global peripheral neuropathy treatment market represents an important part of the neurological treatments market which includes treatment of a common ailment that develops due to impairment of the peripheral nervous system. The condition is characterized by symptoms like pain, numbness, tingling, and muscle weakness which have a huge effect on the quality of patients' lives. The condition results from different causes such as diabetes mellitus, neurotoxicity, resulting from chemotherapy, auto-immune responses, infection, and genetics, among others

The market is experiencing substantial growth owing to increasing prevalence of diabetes around the globe, increased geriatric population, and high awareness of neuropathy diseases. These factors mean that there is increased number of patients requiring treatment for the condition. Healthcare organizations, as well as manufacturers of medications used to treat peripheral neuropathy, are investing in development of new therapies which not only manage the symptoms, but also help reverse some aspects of the disease.

Market Dynamics

The global peripheral neuropathy treatment market is mainly fueled by the increase in the incidence of Diabetes Mellitus, which is the most common cause of neuropathy and results in almost 50% of people with diabetes experiencing nerve damage, thus forming a large patient population that needs constant therapy. Moreover, the rise in cancer cases has led to an explosion in CIPN cases, owing to the higher survival rate resulting in an increased emphasis on coping with adverse effects of treatment. The increase in the geriatric population base acts as another important driver of the market's growth.

Nevertheless, there exist some difficulties associated with the heterogeneity of peripheral neuropathy. It makes diagnosing the condition and treating it rather problematic. Besides, the regulatory process for innovative drugs, especially pain killers, and the expensive nature of high-quality treatments reduce their availability on a wider scale, specifically in developing countries. Moreover, the lack of reliable biomarkers reduces the speed of developing and testing new medications. Nonetheless, prospects can be found in the creation of disease-modifying agents and digital health technologies, including remote patient monitoring and telemedicine.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global peripheral neuropathy treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Novartis AG, Johnson & Johnson, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, AstraZeneca PLC, Sanofi, and Merck & Co., Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market

Market Segmentation

Indication Insights (Revenue, USD Mn, 2021 - 2033)
- Diabetic Peripheral Neuropathy
- Chemotherapy-induced Peripheral Neuropathy
- Idiopathic Peripheral Neuropathy
- Others
Treatment Insights (Revenue, USD Mn, 2021 - 2033)
- Pharmacological Therapies
- Non-pharmacological Therapies
End User Insights (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Ambulatory Centers
- Others
Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Pfizer Inc.
- Eli Lilly and Company
- Novartis AG
- Johnson & Johnson
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Abbott Laboratories
- AstraZeneca PLC
- Sanofi
- Merck & Co., Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Peripheral Neuropathy Treatment Market, By Indication
- Global Peripheral Neuropathy Treatment Market, By Treatment
- Global Peripheral Neuropathy Treatment Market, By End User
- Global Peripheral Neuropathy Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trends

4. Global Peripheral Neuropathy Treatment Market, By Indication, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Diabetic Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Chemotherapy-induced Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Idiopathic Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global Peripheral Neuropathy Treatment Market, By Treatment, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Non-pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global Peripheral Neuropathy Treatment Market, By End User, 2021-2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Ambulatory Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

7. Global Peripheral Neuropathy Treatment Market, By Region, 2021 - 2033, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial PerTreatmentance
- Strategies

9. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/價格

FAQ

周邊神經病變治療市場：依適應症、治療方法、最終使用者和地區分類。

Peripheral Neuropathy Treatment Market, By Indication, By Treatment, By End User, By Geography

市場動態

本次調查的主要特點

目錄

第1章：研究目標與前提條件

第2章市場範圍

第3章：市場動態、監管與趨勢分析

第4章全球周邊神經神經病變治療市場：依適應症分類，2021-2033年

第5章全球周邊神經病變治療市場：依治療方法，2021-2033年

第6章全球周邊神經病變治療市場：依最終使用者分類，2021-2033年

第7章全球周邊神經神經病變治療市場：依地區分類，2021-2033年

第8章競爭情勢

第9章分析師建議

第10章參考文獻與調查方法

Market Dynamics

Key Features of the Study

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Peripheral Neuropathy Treatment Market, By Indication, 2021-2033, (USD Mn)

5. Global Peripheral Neuropathy Treatment Market, By Treatment, 2021-2033, (USD Mn)

6. Global Peripheral Neuropathy Treatment Market, By End User, 2021-2033, (USD Mn)

7. Global Peripheral Neuropathy Treatment Market, By Region, 2021 - 2033, Value (USD Mn)

8. Competitive Landscape

9. Analyst Recommendations

10. References and Research Methodology

周邊神經病變治療市場：依適應症、治療方法、最終使用者和地區分類。

Peripheral Neuropathy Treatment Market, By Indication, By Treatment, By End User, By Geography

市場動態

本次調查的主要特點

目錄

第1章：研究目標與前提條件

第2章 市場範圍

第3章：市場動態、監管與趨勢分析

第4章 全球周邊神經神經病變治療市場：依適應症分類，2021-2033年

第5章 全球周邊神經病變治療市場：依治療方法，2021-2033年

第6章 全球周邊神經病變治療市場：依最終使用者分類，2021-2033年

第7章 全球周邊神經神經病變治療市場：依地區分類，2021-2033年

第8章 競爭情勢

第9章 分析師建議

第10章 參考文獻與調查方法

Market Dynamics

Key Features of the Study

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Peripheral Neuropathy Treatment Market, By Indication, 2021-2033, (USD Mn)

5. Global Peripheral Neuropathy Treatment Market, By Treatment, 2021-2033, (USD Mn)

6. Global Peripheral Neuropathy Treatment Market, By End User, 2021-2033, (USD Mn)

7. Global Peripheral Neuropathy Treatment Market, By Region, 2021 - 2033, Value (USD Mn)

8. Competitive Landscape

9. Analyst Recommendations

10. References and Research Methodology

第2章市場範圍

第4章全球周邊神經神經病變治療市場：依適應症分類，2021-2033年

第5章全球周邊神經病變治療市場：依治療方法，2021-2033年

第6章全球周邊神經病變治療市場：依最終使用者分類，2021-2033年

第7章全球周邊神經神經病變治療市場：依地區分類，2021-2033年

第8章競爭情勢

第9章分析師建議

第10章參考文獻與調查方法